Your browser doesn't support javascript.
loading
Fevipiprant (QAW039) does not affect the pharmacokinetics of zidovudine, its glucuronide, and penicillin G via inhibition of UGT2B7 and/or OAT3.
Kulkarni, Swarupa; Poller, Birk; Drollmann, Anton; Shah, Bharti; Gray, Cathy; Greco, Erin; Rahmanzadeh, Gholamreza; Hanna, Imad; Weiss, H Markus.
Afiliação
  • Kulkarni S; Novartis Institutes for Biomedical Research, East Hanover, NJ, USA. Electronic address: swarupa.kulkarni@novartis.com.
  • Poller B; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Drollmann A; Novartis Pharma, AG, Basel, Switzerland.
  • Shah B; Novartis Institutes for Biomedical Research, East Hanover, NJ, USA.
  • Gray C; Novartis Institutes for Biomedical Research, East Hanover, NJ, USA.
  • Greco E; Novartis Pharma, AG, Basel, Switzerland.
  • Rahmanzadeh G; Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Hanna I; Novartis Institutes for Biomedical Research, East Hanover, NJ, USA.
  • Weiss HM; Novartis Institutes for Biomedical Research, Basel, Switzerland.
Pulm Pharmacol Ther ; 72: 102097, 2022 02.
Article em En | MEDLINE | ID: mdl-34800680
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Zidovudina / Glucuronídeos Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Zidovudina / Glucuronídeos Idioma: En Ano de publicação: 2022 Tipo de documento: Article